FDA Drug Recalls

Recalls / Class II

Class IID-0746-2022

Product

Janumet (sitagliptin and metformin HCl) tablets, 50 mg/500 mg, 14-count bottle, packaged as 2 bottles per carton , Sample-Not For Sale, Rx Only, Manufactured for Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ 08889, USA, by Patheon Puerto Rico, Inc. Manati, Puerto Rico, 00674 Bottle (NDC 0006-0575-02), Carton (NDC 0006-0575-03)

Brand name
Janumet
Generic name
Sitagliptin And Metformin Hydrochloride
Active ingredients
Metformin Hydrochloride, Sitagliptin Phosphate
Route
Oral
NDCs
0006-0575, 0006-0577
FDA application
NDA022044
Affected lot / code info
Lot: U015824, Exp. 09/22.

Why it was recalled

Presence of foreign substance: Presence of stainless steel particulates in tablets.

Recalling firm

Firm
MERCK SHARP & DOHME CORP
Manufacturer
Merck Sharp & Dohme LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1 Merck Dr, Whitehouse Station, New Jersey 08889-3400

Distribution

Quantity
3600 cartons
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2022-03-31
FDA classified
2022-04-05
Posted by FDA
2022-04-13
Terminated
2023-08-15
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0746-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.